Content
- Rupee is more than a measure of price. It’s also a barometer of credibility
- Global health governance must depend less on FDA
Rupee is more than a measure of price. It’s also a barometer of credibility
Why in News?
- Recent macroeconomic trends (2025–26) show persistent BoP pressures, weak FPI inflows, and rupee volatility, raising concerns over currency stability and macroeconomic credibility.
Issue in Brief
- The Indian Rupee (INR) is not merely an exchange rate variable but a macroeconomic credibility indicator, reflecting investor confidence, capital flows, and external sector stability.
- Sustained depreciation risks triggering inflation, capital flight, and balance sheet stress, undermining long-term economic growth prospects.
Relevance
- GS Paper III: Economy (External Sector, Exchange Rate, Inflation), Banking & Monetary Policy
- GS Paper II: Governance (RBI policy credibility, macroeconomic stability)
Practice Question
- “The exchange rate of a currency reflects not just economic fundamentals but also macroeconomic credibility. Analyse the factors influencing rupee stability and the policy challenges associated with it.” (250 words)
Static Background and Basics
- Exchange rate is the price of one currency in terms of another, determined by demand-supply dynamics in forex markets under managed float regime in India.
- RBI follows a managed floating exchange rate system, intervening to curb excessive volatility without targeting a fixed level.
- India’s forex reserves stood around $640+ billion (2024–25), providing buffer against external shocks.
- Current Account Deficit (CAD) becomes critical as India imports ~85% of crude oil, making rupee sensitive to global commodity prices.
Core Economic Theories
Dornbusch Overshooting Model
- Due to sticky goods prices and flexible financial markets, exchange rates adjust sharply in the short run, often overshooting equilibrium levels before stabilising.
- Explains why currencies fall faster and deeper than macroeconomic fundamentals justify, especially during crises.
Mundell-Fleming Model (Impossible Trinity)
- A country cannot simultaneously maintain:
- Fixed exchange rate
- Free capital mobility
- Independent monetary policy
- India manages trade-offs by allowing partial flexibility in exchange rate with controlled interventions.
Dimensions
Economic Dimension
- Currency depreciation initially improves export competitiveness, but sustained decline leads to imported inflation, especially in oil-dependent economies like India.
- India’s CAD vulnerability persists, as high import dependence offsets export gains from weaker currency.
- Persistent depreciation increases external debt burden, especially for firms with foreign currency borrowings.
Financial and External Sector Dimension
- FPI flows volatile: Positive inflows recorded in only 1 out of last 5 years (till 2026), weakening capital account stability.
- Continued outflows create funding pressure on CAD, increasing dependence on reserves or external borrowing.
- Currency volatility reduces investor confidence, discouraging long-term capital inflows and increasing risk premium.
Inflation and Welfare Dimension
- Depreciation acts as an implicit tax on citizens, increasing cost of imported goods such as fuel, fertilisers, and electronics.
- Leads to cost-push inflation, eroding real incomes and disproportionately affecting poor households.
- Export gains are often neutralised by higher input costs, especially in import-dependent industries.
Governance and Policy Dimension
- RBI faces trade-offs:
- Raising interest rates stabilises currency but slows growth
- Allowing depreciation fuels inflation and instability
- Use of tools like sterilised interventions, swap windows, and reserve requirements reflects calibrated policy response.
Historical Lessons
Global Financial Crisis (2008–09)
- RBI reduced repo rate from 9% to 4.75%, injected ₹2.25 lakh crore liquidity, stabilising markets.
- Fiscal stimulus of ~3% of GDP boosted demand but raised fiscal deficit to 6.5% of GDP.
Taper Tantrum (2013)
- Rupee depreciated ~20%, triggered by US Fed policy signals.
- Policy response:
- FCNR(B) deposit schemes
- Oil swap windows
- Gold import duty hike (6% → 10%)
- CAD reduced from 4.8% to 1.3% of GDP, restoring macro stability.
Global and Structural Dimension
- Emerging markets like Turkey, Brazil faced severe inflation due to currency depreciation, highlighting limits of export-led devaluation strategies.
- Persistent depreciation reflects structural weaknesses: low export diversification, energy dependence, and weak manufacturing base.
Geopolitical and Trade Dimension
- External pressures such as tariffs, Section 301 investigations, geopolitical tensions, and AI-driven trade disruptions influence currency volatility.
- Global monetary tightening cycles amplify capital outflows from emerging markets like India.
Challenges and Risks
- Persistent BoP deficit and weak capital inflows create sustained downward pressure on rupee stability.
- Over-reliance on monetary tools risks policy ineffectiveness during supply-side shocks like oil price spikes.
- High import dependence in energy and electronics limits benefits of depreciation-led export competitiveness.
- Currency volatility increases corporate balance sheet risks, especially for firms with unhedged foreign liabilities.
- Rising reputation risk may deter both new and existing investors, affecting long-term capital formation.
Way Forward
- Strengthen external sector resilience by diversifying exports and reducing dependence on imported inputs, especially in energy and electronics sectors.
- Enhance energy security through renewable expansion and strategic reserves to reduce oil import vulnerability.
- Improve investment climate via policy stability, ease of doing business, and regulatory predictability to attract sustained FDI inflows.
- Use coordinated monetary-fiscal strategy, avoiding excessive reliance on interest rate adjustments during supply shocks.
- Expand inclusion of petroleum products and electricity under GST to improve fiscal efficiency and reduce cascading costs.
- Maintain adequate forex reserves buffer and deploy calibrated interventions to prevent disorderly currency movements.
Prelims Pointers
- India follows managed floating exchange rate system
- CAD + capital flows = Balance of Payments (BoP)
- Dornbusch Model → explains exchange rate overshooting
- Mundell-Fleming → Impossible Trinity concept
- FCNR(B) deposits used during 2013 crisis stabilisation
Global health governance must depend less on FDA
Why in News?
- Recent 2025–2026 developments within the US FDA, including leadership turnover, regulatory shifts, and policy changes in AI and biologics, have raised concerns over global regulatory stability.
Issue in Brief
- The US Food and Drug Administration (FDA) acts as a global benchmark regulator, influencing drug approvals, clinical trials, and regulatory standards across multiple countries.
- Current institutional instability within FDA risks delays, uncertainty, and cascading disruptions in global drug approval ecosystems.
Relevance
- GS Paper II: International Relations, Global Health Governance, Institutions
- GS Paper III: Science & Technology (Pharma, Biotech regulation)
Practice Question
- “Excessive reliance on a single national regulator like the US FDA creates systemic risks in global health governance. Critically examine and suggest alternatives.” (250 words)
Static Background and Basics
- The U.S. Food and Drug Administration was established in 1906 (Pure Food and Drugs Act) and operates under the US Department of Health and Human Services.
- It regulates drugs, vaccines, biologics, medical devices, diagnostics, and food safety, covering products worth ~20% of US consumer spending.
- Other key global regulators include:
- European Medicines Agency (EU)
- Central Drugs Standard Control Organisation (India)
- Global regulatory cooperation guided by International Council for Harmonisation (ICH) ensures standardisation of safety, quality, and efficacy norms.
Conceptual Foundation: Regulatory Reliance Model
- Many low- and middle-income countries adopt “regulatory reliance pathways”, using approvals from FDA/EMA to fast-track domestic approvals without duplicating full review processes.
- This reduces:
- Approval timelines
- Regulatory burden
- Ensures minimum global safety standards despite limited domestic capacity.
Dimension
Governance and Institutional Dimension
- FDA serves as a de facto global standard-setter, influencing regulatory frameworks, clinical trial norms, and approval pathways across developing and developed economies.
- Leadership instability in critical divisions (e.g., biologics) creates policy uncertainty in high-risk areas like vaccines and gene therapy regulation.
- Budget constraints and structural reforms within FDA may reduce institutional predictability and regulatory consistency globally.
Global Health Governance Dimension
- Over-reliance on FDA creates systemic vulnerability, where regulatory disruptions in one country affect multiple national health systems.
- Highlights need for multipolar regulatory architecture, reducing concentration of authority in a single institution.
- Strengthening regional regulators improves resilience and decentralisation in global health governance systems.
Economic and Pharmaceutical Industry Dimension
- FDA approval is considered gold standard for global market access, influencing investment decisions and pharmaceutical R&D strategies.
- Pharmaceutical companies design clinical trials aligned with FDA standards, affecting global research protocols and innovation pipelines.
- Regulatory uncertainty increases cost of compliance and delays product commercialisation, affecting global supply chains.
Science and Technology Dimension
- FDA plays a critical role in regulating emerging technologies such as AI in healthcare, digital health tools, and clinical decision support systems.
- Changes in FDA guidelines influence global standards for AI validation, safety protocols, and ethical use in medicine.
- Instability may slow adoption of cutting-edge innovations like gene therapy and personalised medicine.
Social and Ethical Dimension
- Delays in approvals due to regulatory uncertainty affect timely access to life-saving medicines and vaccines, especially in developing countries.
- Raises concerns of equity in global health, as countries dependent on FDA may face delays in access to critical healthcare technologies.
- Over-centralisation of regulatory authority raises ethical issues of global dependence on a single national institution.
India-Specific Dimension
- India’s Central Drugs Standard Control Organisation increasingly aligns with global standards but still relies partly on FDA approvals for accelerated pathways and benchmarking.
- India is expanding regulatory capacity through:
- Strengthening CDSCO
- Enhancing clinical trial ecosystem
- Presents opportunity to emerge as a regional regulatory hub for Global South countries.
Challenges and Risks
- Excessive reliance on FDA creates systemic regulatory dependency, limiting autonomy of national regulators in decision-making.
- Leadership turnover within FDA introduces uncertainty in approval timelines, especially in biologics and advanced therapies.
- Divergence in regulatory standards may increase compliance burden for global pharmaceutical firms.
- Limited capacity in developing countries constrains their ability to independently evaluate complex drugs and technologies.
- Fragmentation of regulatory standards could lead to inconsistent safety and efficacy benchmarks globally.
Way Forward
- Strengthen national regulatory institutions like CDSCO, enhancing technical capacity, staffing, and infrastructure for independent drug evaluation.
- Promote regional regulatory cooperation frameworks (e.g., Asia-Africa collaboration) to reduce dependence on Western regulators.
- Enhance participation in ICH and WHO regulatory harmonisation initiatives to align global standards while maintaining autonomy.
- Develop robust domestic clinical trial ecosystems, reducing reliance on foreign regulatory benchmarks.
- Encourage multi-regulator validation models, where approvals consider inputs from multiple global agencies rather than a single authority.
- Invest in AI-driven regulatory tools to improve efficiency, transparency, and speed of drug approval processes.
Prelims Pointers
- FDA established: 1906 (Pure Food and Drugs Act)
- FDA regulates:
- Drugs, biologics, devices, food
- EMA:
- European Union drug regulator
- CDSCO:
- India’s national drug regulatory authority
- ICH:
- Harmonises global drug regulatory standards
